000256605 001__ 256605
000256605 005__ 20240112171657.0
000256605 0247_ $$2doi$$a10.1186/s40035-023-00342-4
000256605 0247_ $$2pmid$$apmid:36915212
000256605 0247_ $$2pmc$$apmc:PMC10012698
000256605 0247_ $$2ISSN$$a2047-9158
000256605 0247_ $$2ISSN$$a2096-6466
000256605 0247_ $$2altmetric$$aaltmetric:143903651
000256605 037__ $$aDZNE-2023-00357
000256605 041__ $$aEnglish
000256605 082__ $$a570
000256605 1001_ $$0P:(DE-2719)9000287$$aSchmitz, Matthias$$b0$$eFirst author$$udzne
000256605 245__ $$aα-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies.
000256605 260__ $$aLondon$$bBiomed Central$$c2023
000256605 3367_ $$2DRIVER$$aarticle
000256605 3367_ $$2DataCite$$aOutput Types/Journal article
000256605 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1680684658_8248$$xReview Article
000256605 3367_ $$2BibTeX$$aARTICLE
000256605 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000256605 3367_ $$00$$2EndNote$$aJournal Article
000256605 500__ $$aCC BY
000256605 520__ $$aα-Synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, are a class of neurodegenerative diseases exhibiting intracellular inclusions of misfolded α-synuclein (αSyn), referred to as Lewy bodies or oligodendroglial cytoplasmic inclusions (Papp-Lantos bodies). Even though the specific cellular distribution of aggregated αSyn differs in PD and DLB patients, both groups show a significant pathological overlap, raising the discussion of whether PD and DLB are the same or different diseases. Besides clinical investigation, we will focus in addition on methodologies, such as protein seeding assays (real-time quaking-induced conversion), to discriminate between different types of α-synucleinopathies. This approach relies on the seeding conversion properties of misfolded αSyn, supporting the hypothesis that different conformers of misfolded αSyn may occur in different types of α-synucleinopathies. Understanding the pathological processes influencing the disease progression and phenotype, provoked by different αSyn conformers, will be important for a personalized medical treatment in future.
000256605 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000256605 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000256605 650_2 $$2MeSH$$aHumans
000256605 650_2 $$2MeSH$$aalpha-Synuclein: genetics
000256605 650_2 $$2MeSH$$aalpha-Synuclein: metabolism
000256605 650_2 $$2MeSH$$aSynucleinopathies: diagnosis
000256605 650_2 $$2MeSH$$aSynucleinopathies: genetics
000256605 650_2 $$2MeSH$$aSynucleinopathies: metabolism
000256605 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000256605 650_2 $$2MeSH$$aParkinson Disease: genetics
000256605 650_2 $$2MeSH$$aParkinson Disease: metabolism
000256605 650_2 $$2MeSH$$aLewy Bodies: pathology
000256605 650_2 $$2MeSH$$aMultiple System Atrophy: diagnosis
000256605 650_2 $$2MeSH$$aMultiple System Atrophy: genetics
000256605 650_2 $$2MeSH$$aMultiple System Atrophy: pathology
000256605 650_7 $$2Other$$aα-synuclein
000256605 650_7 $$2Other$$aProtein strains
000256605 650_7 $$2Other$$aRT-QuIC
000256605 650_7 $$2Other$$aα-synuclein
000256605 650_7 $$2Other$$aα-synucleinopathies
000256605 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000256605 650_7 $$2Other$$aα-synucleinopathies
000256605 7001_ $$0P:(DE-2719)9000041$$aCandelise, Niccolò$$b1$$udzne
000256605 7001_ $$0P:(DE-2719)9001944$$aCanaslan, Sezgi$$b2$$udzne
000256605 7001_ $$aAltmeppen, Hermann C$$b3
000256605 7001_ $$aMatschke, Jakob$$b4
000256605 7001_ $$aGlatzel, Markus$$b5
000256605 7001_ $$0P:(DE-2719)9001558$$aYounas, Neelam$$b6$$udzne
000256605 7001_ $$0P:(DE-2719)9000358$$aZafar, Saima$$b7$$udzne
000256605 7001_ $$0P:(DE-2719)2812183$$aHermann, Peter$$b8$$udzne
000256605 7001_ $$0P:(DE-2719)2000058$$aZerr, Inga$$b9$$eLast author$$udzne
000256605 773__ $$0PERI:(DE-600)2653701-1$$a10.1186/s40035-023-00342-4$$gVol. 12, no. 1, p. 12$$n1$$p12$$tTranslational neurodegeneration$$v12$$x2047-9158$$y2023
000256605 8564_ $$uhttps://pub.dzne.de/record/256605/files/DZNE-2023-00357.pdf$$yOpenAccess
000256605 8564_ $$uhttps://pub.dzne.de/record/256605/files/DZNE-2023-00357.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000256605 909CO $$ooai:pub.dzne.de:256605$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000256605 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000287$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000256605 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000041$$aExternal Institute$$b1$$kExtern
000256605 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001944$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000256605 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001558$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000256605 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000358$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000256605 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812183$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000256605 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000058$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000256605 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000256605 9141_ $$y2023
000256605 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-12
000256605 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000256605 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-12
000256605 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-12
000256605 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000256605 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-12
000256605 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRANSL NEURODEGENER : 2022$$d2023-08-29
000256605 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-29
000256605 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-29
000256605 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-29
000256605 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:08Z
000256605 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:08Z
000256605 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:08Z
000256605 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-29
000256605 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-29
000256605 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-29
000256605 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-29
000256605 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bTRANSL NEURODEGENER : 2022$$d2023-08-29
000256605 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarkers$$x0
000256605 9201_ $$0I:(DE-2719)5000037$$kExt UMG Zerr$$lExt UMG Zerr$$x1
000256605 9201_ $$0I:(DE-2719)1440015$$kClinical Dementia Research Göttingen$$lClinical Dementia Research Göttingen$$x2
000256605 980__ $$ajournal
000256605 980__ $$aVDB
000256605 980__ $$aUNRESTRICTED
000256605 980__ $$aI:(DE-2719)1440011-1
000256605 980__ $$aI:(DE-2719)5000037
000256605 980__ $$aI:(DE-2719)1440015
000256605 9801_ $$aFullTexts